Skip to main content
. 2009 Aug 19;114(15):3255–3264. doi: 10.1182/blood-2009-06-229898

Table 1.

Patients' characteristics of miRNA screening cohort

Negative for feature, n/% Positive for feature, n/%
Thymidine kinase (> 10 U/L) 34/50 (68.0%) 16/50 (32.0%)
CD38 (> 10% positive CLL cells) 34/50 (68.0%) 16/50 (32.0%)
ZAP70 (> 20% positive CLL cells) 25/50 (50.0%) 25/50 (50.0%)
IgVH hypermutational status (homology > 98%) 20/31 (64.5%) 11/31 (35.4%)

Molecular features of 50 patients being diagnosed with CLL were assessed before miRNA profiling was performed.